68 results about "Chikungunya" patented technology

The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.

The invention relates to a preparation method of virus-like particles (VLPs) of Chikungunya virus (CHIKV). The method comprises the steps of: modifying genetic elements of a structural protein encoding gene C-E3-E2-6K-E1 of CHIKV, cloning the modified genetic elements into the expression vector of an insect cell, then transfecting the obtained recombined expression vector and baculovirus linear DNA respectively to an SF9 insect cell and making the cell secrete and express CHIKV VLPs. Additionally, the invention also makes preliminary studies on the immune effects of CHIKV VLPs and applicationof CHIKV VLPs in virus specific antibody detection, thus laying a foundation for research and preparation of immunological detection reagents and even vaccines based on CHIKV VLPs.

A virus like particle comprising a viral structural protein which comprises modified envelope protein E3. The viral structural protein may be that derived from or alphavirus or flavivirus. Especially, the viral structural protein may be derived from Chikungunya virus or Venezuelan equine encephalitis virus.

Consensus CHIKV E1 protein, consensus CHIKV E2 protein, consensus CHIKV capsid protein, or fragments and homologues thereof, and nucleic acid molecules that encode the same are disclosed. A consensus CHIKV Env protein which includes CHIKV E1 consensus protein, CHIKV E2 consensus protein, CHIKV E3 consensus protein, or fragments and homologues thereof and nucleic acid molecules that encode the same are also disclosed. Compositions and recombinant vaccines comprising CHIKV consensus proteins, and methods of using them are disclosed.

The present invention is directed to compounds, compositions and methods for treating or preventing viral infections using nucleoside analog monophosphate prodrugs. More specifically, HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever in human patients or other animal hosts. The compounds are certain 2,6-diamino 2-C-methyl purine nucleoside monophosphate prodrugs and modified prodrug analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever. This invention teaches how to modify the metabolic pathway of 2,6-diamino 2'-C-methyl purine and deliver nucleotide triphosphate(s) to polymerases at heretofore unobtainable therapeutically-relevant concentrations.

The present invention discloses a chimeric Chikungunya virus comprising a heterologous alphavirus cDNA fragment and a Chikungunya virus cDNA fragment. The heterologous alphavirus may include but is not limited to Sindbis virus, Eastern equine encephalitis virus or Venezuelan equine encephalitis virus. The present invention also discloses the use of this chimeric Chikungunya virus as vaccines and in serological and diagnostic assays.

Described herein are improved purification methods for virus vaccines and compositions. Also described are Zika, Chikungunya, dengue and yellow fever vaccines and methods of producing and administering said vaccines to subjects in need thereof.

The invention relates to the technical field of virus detection, and concretely relates to a method for detecting Zika virus, Chikungunya virus and Mayaro virus by triple real-time fluorescent quantitative RT-PCR. The method combines the probability of occurrence of related mosquito-borne pathogens, the risk of prevalence, and the operability of a laboratory testing procedure, the Mayaro virus isused to replace the dengue virus in an existing common combination detection scheme, and a new detection scheme using Zika virus, Chikungunya virus and Mayaro virus as detection targets is formed. Theinvention provides a specific primer, a probe and a triple real-time quantitative RT-PCR detection method for simultaneously identifying the viral pathogens Zika virus, Chikungunya virus and Mayaro virus which are transmitted by Aedes mosquito and cause similar clinical symptoms of diseases. The method has high specificity and sensitivity, good repeatability, simple and rapid detection, and costsaving, and can complement a traditional detection scheme and has high application value.

The invention relates to recombinant Measles virus expressing Chikungunya virus polypeptides, and concerns in particular virus like particles (VLP) that contain envelope and capsid proteins of a Chikungunya virus at their surface. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Chikungunya virus.

The present invention relates to the use of increased culture pH, relative to standard insect cell culture conditions, during baculovirus infection of lepidopteran insect cells to enable production of recombinant chikungunya (CHIKV) virus like particles (VLPs). The invention further relates to adapted insect cell lines derived from insect cells such as Sf21, which can grow robustly at elevated culture pH, the use of said cell lines to recombinantly produce pH sensitive proteins in the correct conformation and increase expression of recombinant proteins relative to standard insect cell lines. In some embodiments of the invention, the cells are useful for recombinant production of CHIKV VLPs. The invention also relates to a method for the production of a pH-adapted lepidopteran insect cell line. In some embodiments of said method, the cell line is produced and / or maintained in reduced phosphate serum-free insect cell media.

The present invention concerns antibodies and antigen-binding fragments of antibodies which specifically bind to and neutralize Chikungunya virus (CHIKV) and which are engineered to develop therapeutics in order to treat CHIKV disease or prevent CHIKV infection. The invention also relates to pharmaceutical compositions comprising antibodies of the invention and the use of the antibodies for the prevention and treatment of CHIKV disease.

The invention discloses a cyclocompound of tetrahydropyrrole and dihydroimidazolone as well as preparation and pharmaceutical application thereof. The cyclocompound is a compound shown in a formula (I), an isomer or pharmaceutically acceptable salt thereof. The compound, isomer or pharmaceutically acceptable salt thereof can be applied to preparation of medicines used for preventing or treating related diseases (such as dengue fever, dengue hemorrhagic fever, dengue shock syndrome, Zika, Chikungunya, Japanese encephalitis, yellow fever, hepatitis C and West Nile disease) caused by a dengue fever virus and related viruses. (The formula (I) is described in the specification).

The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV and influenza infection and cancer in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.

The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.

The present invention relates to immunogenic peptides of Chikungunya Virus and methods for vaccinating a subject using these peptides. Also disclosed are nucleic acids encoding these peptides and methods for their production.

The invention discloses a triple detection method of arbovirus liquid chips. The method comprises the following steps: respectively designing specific primers and probes aiming at three types of arboviruses comprising Chikungunya viruses, Crimean-Congo hemorrhagic fever and Rift Valley fever viruses, determining the specificity of the primers and the probes via a single PCR and clone sequencing, and then carrying out multiplex-PCR amplification under the condition that the concentration ratio of the forward and reverse primers in an amplification reaction system is 1:1-1:8; then coupling the probes with fluorescent coding microspheres so as to prepare a microsphere mixing liquid and carrying out coupling quality control by coupling the probes; finally, carrying out a hybridization reaction on multiplex-PCR products and the microsphere mixing liquid, simultaneously adding streptomycin-phycoerythrin diluted by a nucleic acid detection buffer solution, and analyzing reaction products by utilizing a liquid chip detecting instrument. The method is good in detection specificity and can be used for simultaneously detecting the three types of arboviruses, and has high detection sensitivity due to the adoption of an asymmetric PCR amplification method in the process of the multiplex-PCR amplification.

Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient.

This invention relates to compositions and methods for the differential detection of multiple viruses using a one-step assay. The viruses to be detected include Zika, West Nile, dengue (genotype 1-4)and chikungunya viruses. In particular, the invention relates to a method of and assay for differential detection of the viruses using specific primers and probes designed to detect and differentiatebetween the viruses.

The present invention discloses a DNA molecule having a nucleotide sequence represented by SEQ ID NO:1, and uses thereof, and further discloses a Chikungunya virus DRDE-06 strain labeling method, recombinant plasmid containing the DNA molecule, a construction method of the recombinant plasmid, infectious clone of the Chikungunya virus having the genomic RNA corresponding cDNA nucleotide sequence represented by SEQ ID NO:1, and a construction method of the infectious clone. According to the present invention, the DNA molecule or the recombinant plasmid can be used for constructing the Chikungunya virus infectious clone having the performance similar to the wild-type virus.

The invention relates to the technical field of biological medicines, and provides an amino acid sequence of a chikungunya virus (CHIKV) E2 protein rabbit monoclonal antibody and application thereof. The amino acid sequence of the CHIKV E2 protein rabbit monoclonal antibody comprises an amino acid sequence of a heavy chain and an amino acid sequence of a light chain of the antibody. The antibody expressed by mammalian cells can neutralize infection of CHIKV genotypes which are mainly popular in the world on the cells in vitro, and can protect type I interferon receptor genes from knocking out mice to resist fatal CHIKV infection in vivo. The antibody is modified, such as humanized modification or preparation of a single-chain antibody, and is expected to be used for treating severe CHIKV infection.

The invention discloses a method for detecting Chikungunya virus nucleic acid by real-time fluorescent quantitative PCR, comprising: obtaining a primer and a probe, and detecting the Chikungunya virus nucleic acid. The invention has the advantages of good specificity, high sensitivity and the like.

A novel technique for label-free, rapid detection of ultra-low concentrations of virus specific antibodies is described. We have developed a simple, robust capacitive biosensor using microwires coated with Zika or Chikungunya virus envelope antigen. With little discernable nonspecific binding, the sensor can detect as few as 10 antibody molecules in a small volume (10 molecules / 30 μL) within minutes. It can also be used to rapidly, specifically, and accurately determine the isotype of antigen-specific antibodies. Finally, we demonstrate that anti-Zika virus antibody can be sensitively and specifically detected in dilute mouse serum and can be isotyped using the sensor. Overall, our findings indicate that our microwire sensor platform can be used as a reliable, sensitive, and inexpensive diagnostic tool to detect immune responses at the point of care.

The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.

The invention discloses a Chikungunya virus specific detection antigen and an application thereof. The Chikungunya virus specific detection antigen provided by the invention is a polypeptide shown as any of (a1), (a2) and (a3), wherein (a1) is a polypeptide shown as a sequence 1 or a 166-378 site of the sequence 1; (a2)is a polypeptide shown as a sequence 2 or a 166-392 site of the sequence 2; and (a3) is a polypeptide which is obtained by performing substitution and / or deletion and / or addition of one or more amino acid residues on an amino acid sequence of the polypeptide defined by any of (a1) and (a2)and has the same function as the polypeptide defined by any of (a1) and (a2). The Chikungunya virus specific detection antigen has relatively high specificity and sensitivity in detection of Chikungunya virus serum infection.

The present invention refers to a composition comprising a viral protein or fragment thereof, wherein the viral protein or fragment thereof is enclosed within a self-assembling protein nanocapsule, preferably ferritin, and wherein the viral protein, or fragment thereof is selected from a virus of the Togaviridae family. The viral protein or fragment thereof may also further be selected from a virus of the alphavirus subfamily.